


HD-TAC7

Cat. No.:	HY-146346
CAS No.:	2978763-95-8
Molecular Formula:	C ₃₃ H ₃₂ N ₇ O ₇
Molecular Weight:	657.65
Target:	PROTACs; HDAC
Pathway:	PROTAC; Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HD-TAC7 is a potent PROTAC HDAC degrader with IC ₅₀ values of 3.6 μM, 4.2 μM and 1.1 μM for HDAC1, HDAC2 and HDAC3, respectively. HD-TAC7 can decrease NF-κB p65 in RAW 264.7 macrophages. HD-TAC7 can be used for the research of inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD) ^[1] .		
IC ₅₀ & Target	HDAC1 3.6 μM (IC ₅₀)	HDAC2 4.2 μM (IC ₅₀)	HDAC3 1.1 μM (IC ₅₀)
In Vitro	HD-TAC7 (10 μM; 24 hours) induces an increase of H3K27 acetylation in RAW 264.7 macrophages ^[1] . HD-TAC7 (10 μM; 2-48 hours) induces HDAC3 degradation reaching the maximal effect at 6h and lasted at least 48h ^[1] . HD-TAC7 (1 and 10 μM; 24 hours) downregulates NF-κB p65 in LPS-treated RAW 264.7 macrophages ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Fangyuan Cao, et al. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). Eur J Med Chem. 2020 Dec 15;208:112800.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA